BioSpace News Archive

Zynerba Pharmaceuticals, Inc. announced that the new date for the adjourned 2023 Annual Meeting of Stockholders is August 11, 2023 at 9:00 a.m. EDT.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received approval to conduct clinical trial of its second generation pan-TRK inhibitor zurletrectinib (ICP-723) to treat pediatric patients (2 to 12 years old) in China.

Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV) today announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president and head, investor relations and corporate affairs.

RedHill Biopharma Ltd. announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,301,923 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $1.35 per ADS.

QuidelOrtho Corporation announced that it has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2023 IMV ServiceTrak Awards for the sixth consecutive year.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Infinity Pharmaceuticals, Inc. announced a series of actions designed to reduce the Company’s burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc.

Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, has announced that their abstract from the Revolutionizing Atopic Dermatitis (RAD) Conference has been published in the British Journal of Dermatology.

Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases recently announced its support of the Immune Deficiency Foundation Research Grant Program for the second year in a row.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023.